NA

BLENREP efficacy

Learn how fast, deep and durable responses to BLENREP were in a triple-class refractory multiple myeloma (MM) patient population1-3

For GB healthcare professionals only.*

Table of contents

DREAMM-2 clinical trial

The DREAMM-2 clinical trial studied BLENREP as a single agent in triple-class refractory patients with multiple myeloma (MM) (n=97; 13-month follow-up) who had received a median of 7 prior lines of therapy.1

BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.2,3

  • DREAMM-2 clinical trial design

    • DREAMM-2 was an open-label, multicentre, phase 2 study in patients with relapsed/refractory multiple myeloma2
    • Patients were refractory to an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulatory agent2
    DREAMM-2 study design

    HSCT, haematopoietic stem cell transplantation.

  • DREAMM-2 patient characteristics

    Baseline characteristics in the recommended dose population2

    Adapted from Lonial S, et al. Lancet Oncol. 2020. Data are n (%) unless otherwise specified.

    eGFR, estimated glomerular filtration rate; IgG, immunoglobulin G; ISS, International Staging System.
    *Data available for 47 patients in the 2.5 mg/kg cohort and 36 patients in the 3.4 mg/kg cohort.2
    The number of previous lines of therapy is derived as the number of previous anticancer regimens received by a patient as reported on the electronic case report form. Combination therapy containing multiple components was counted as one regimen.2
    Based on data available at the time of database lock; however, all patients were refractory to a proteasome inhibitor, immunomodulatory drug,and an anti-CD38 monoclonal antibody as per eligibility criteria.2

DREAMM-2 efficacy data for BLENREP

DREAMM-2 results at 13 month follow up

Watch Dr Rakesh Popat present the DREAMM-2 clinical trial, including DREAMM-2 efficacy results, safety data, and how eye-related side effects were managed.

BLENREP can deliver deep responses in patients with triple-class refractory MM1

Primary endpoint: ORR1
Overall, 32% of patients (N=31/97; 97.5% CI: 21.7-43.6) responded to BLENREP at 13-month follow up1

ORR bar chart

Adapted from Lonial S, et al. Cancer. 2021.

BLENREP can deliver durable responses in patients with triple-class refractory MM1

DREAMM-2 results at 13 month follow up

Secondary endpoint: OS1

Results at 13-month follow up: median OS was 13.7 months (95% CI: 9.9-NR).1

OS graph

Adapted from Lonial S, et al. Cancer. 2021.
CI, confidence interval; NR, not reached; OS, overall survival.

OS by response category1

Median OS not reached for responding patients at 13-month follow-up.1

OS by response graph

Adapted from Lonial S, et al. Cancer. 2021.
MR, minimal response; NE, not evaluable; PD, progressive disease; PR, patrial response; SD, stable disease.

DREAMM-2 results at 13 month follow up

Duration of response (DoR)1

The median duration of response was 11.0 months (95% CI; 4.2-NR)

DoR graph

Adapted from Lonial S, et al. Cancer. 2021.
CI, confidence interval; DoR, duration of response; MR, minimal response; NR, not reached; PR, partial response.

DREAMM-2 results at 13 month follow up

The estimated duration of clinical benefit (MR or better) was 11.7 months (95% CI: 4.2-NR)1

Clinical benefit graph

Adapted from Lonial S, et al. Cancer. 2021.
CI, confidence interval; MR, minimal response; NR, not reached.

DREAMM-2 results at 13 month follow up

Progression-free survival (PFS)1

Median PFS was 2.8 months (95% CI: 1.6-3.6).1

PFS graph

Adapted from Lonial S, et al. Cancer. 2021.
CI, confidence interval; PFS, progression-free survival.

DREAMM-2 results at 13 month follow up

PFS by response category1

BLENREP delivered greater than 12 months progression-free survival in patients with a minimal response or better.1

PFS by response graph

Adapted from Lonial S, et al. Cancer. 2021.
MR, minimal response; NE, not estimable; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.

BLENREP can deliver fast responses in patients with triple-class refractory MM3

DREAMM-2 results at 13-month follow up

Response time infograpics

TTBR, time to best response; TTR, time to response

Personalising care with BLENREP

MM typically affects elderly patients who often face additional challenges such as:4

It is therefore important to employ a personalised approach when choosing a treatment option in these patients.4

BLENREP delivered similar responses in patient sub-groups vs. the overall population1

Analysis at 13 month follow up

High-risk patients ORR chart

*Analysis included patients with t(4;14), t(14;16), or 17p13del translocations. Evaluation of BLENREP in patients with these high-risk cytogenetics was a prespecified subgroup analysis and not adjusted for multiplicity. In a post-hoc analysis that also included patients with the 1q21+ abnormality, the ORR was 29% (n=12/41; 95% CI: 16.1–45.5).1

ORR based on renal function (post-hoc analysis)1

Renal function ORR
Normal renal function
(≥90 mL/min/1.73 m2; n=19)
37% (95% CI: 16.3-61.6)
Mild renal impairment
(≥60–<90 mL/min/1.73 m2; n=48)
33% (95% CI: 20.4-48.4)
Moderate renal impairment
(≥30–<60 mL/min/1.73 m2; n=24)
33% (95% CI: 15.6-55.3)
 
 
Discover the safety outcomes for BLENREP

*BLENREP is not commercially available in Northern Ireland.

BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.3

Abbreviations

CI, confidence interval; DoR, duration of response; DREAMM-2, DRiving Excellence in Approaches to Multiple Myeloma 2; eGFR, estimated glomerular filtration rate; HSCT, haematopoietic stem cell transplantation; IgG, immunoglobulin G; ISS, International Staging System; MM, multiple myeloma; MR, minimal response; NE, not evaluable; NR, not reached; OS, overall survival; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; TTBR, time to best response; TTR, time to response; VGPR, very good partial response.

References

  1. Lonial S, et al. Cancer. 2021;127(22):4198–4212.
  2. Lonial S, et al. Lancet Oncol. 2020;21(2):207–221.
  3. BLENREP Summary of Product Characteristics.
  4. Palumbo A, et al. Blood. 2011;118(17):4519–4529.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

October 2022 | PM-GB-BLM-WCNT-220003 (V1.0)